SCHEMBL16447012

SCHEMBL16447012

COc1ccc(-c2nc(C)c3cc[nH]c3n2)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.44
▸ NPC1 O15118 4/20 0.44
▸ RAB9A P51151 4/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ KDM4E B2RXH2 5/20 0.43
▸ MAPT P10636 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ PDGFRB P09619 1/20 0.43
▸ PDGFRA P16234 1/20 0.43
▸ TGFBR1 P36897 1/20 0.43
▸ TGFBR2 P37173 1/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ ABCG2 Q9UNQ0 2/20 0.40
▸ ABCB1 P08183 1/20 0.40
▸ ABCC1 P33527 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16446816 0.84 ALDH1A1 (0.46) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL16446457 0.77 TRPA1 (0.42) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL25082162 0.76 ABCG2 (0.58) SMN1; SMN2MEN1KMT2AMAPTLMNA
SCHEMBL16446732 0.73 NR3C1 (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL13655439 0.71 KMT2A (0.63) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL30611601 0.71 TRPA1 (0.42) TGFBR1TGFBR2TRPA1
SCHEMBL5031343 0.70 RAB9A (0.57) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL8366781 0.70 RAB9A (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL29721888 0.70 BRD4 (0.43) PDGFRBTGFBR1TGFBR2TRPA1KIT
SCHEMBL23147921 0.70 BRD4 (0.43) PDGFRBTGFBR1TGFBR2TRPA1KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP ALDH1A1 462/4885NPC1 2339/4885RAB9A 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback